Rami Skaliter

Despite promising results in preclinical models, cell therapies for ocular disease continue to face critical translational challenges from low post-injection viability and cell migration to structural disorganization and immune rejection. This workshop will examine how delivery innovations like hydrogel encapsulation, patient specific sourcing, and immunomodulatory strategies are reshaping the future of retinal cell therapy.

Key Topics to be Explored:

• Cell therapy product in ready to administer formulation for different indications
• How natural mechanisms can help overcome immune rejection
• The key elements needed to move cell therapies into clinical trials for degenerative retinal diseases